Cyclosporine Ophthalmic

Major

Cyclosporine Ophthalmic Piketoprofen An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Pimozide Increased pimozide exposure Details Cyclosporine Ophthalmic Piperaquine Increased exposure of piperaquine and CYP3A4 substrates Details Cyclosporine Ophthalmic Piroxicam Feldene An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Pirtobrutinib Jaypirca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Cyclosporine Ophthalmic Pixantrone Increased exposure to pixantrone Details Cyclosporine Ophthalmic Poliovirus Vaccine, Live An inadequate immunological response to the vaccine, increased risk of disseminated infection with live vaccines and reduced effic... Details Cyclosporine Ophthalmic Posaconazole Noxafil Increased cycloSPORINE exposure and an increased posaconazole exposure Details Cyclosporine Ophthalmic Potassium Phosphate K-Phos Increased risk of severe and potentially fatal hyperkalemia Details Cyclosporine Ophthalmic Pralsetinib Gavreto Increased pralsetinib exposure and an increased risk of pralsetinib-related adverse events Details Cyclosporine Ophthalmic Pranoprofen An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Pravastatin Pravachol Increased pravastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Cyclosporine Ophthalmic Primidone Mysoline Reduced cycloSPORINE exposure and reduced efficacy of cycloSPORINE Details Cyclosporine Ophthalmic Proglumetacin An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Propafenone Rythmol Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Propyphenazone An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Proquazone An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Pyrazinamide Zinamide® Reduced cycloSPORINE serum concentrations and potentially reduced immunosuppressive efficacy Details Cyclosporine Ophthalmic Quinapril Accupril Acute renal dysfunction and an increased risk of hyperkalemia Details Cyclosporine Ophthalmic Quinidine Cardioquin® Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Quinine Increased cycloSPORINE exposure and increased quiNINE exposure Details Cyclosporine Ophthalmic Ramipril Altace Acute renal dysfunction and an increased risk of hyperkalemia Details Cyclosporine Ophthalmic Ranitidine Increased risk of renal dysfunction and an increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Ranolazine Aspruzyo Increased cycloSPORINE exposure and an increased ranolazine exposure Details Cyclosporine Ophthalmic Red Yeast Rice An increased risk of elevated creatine phosphokinase (CPK) values Details Cyclosporine Ophthalmic Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Cyclosporine Ophthalmic Relugolix Orgovyx Increased relugolix exposure Details Cyclosporine Ophthalmic Remibrutinib Rhapsido Increased P-gp substrate exposure and an increased risk of P-gp substrates-related adverse reactions Details Cyclosporine Ophthalmic Repotrectinib Augtyro Increased repotrectinib exposure, an increased risk of repotrectinib-related adverse effects, reduced cycloSPORINE exposure and re... Details Cyclosporine Ophthalmic Revefenacin Yupelri Increased exposure of the active metabolite of revefenacin Details Cyclosporine Ophthalmic Ribociclib Kisqali Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Cyclosporine Ophthalmic Rifabutin Mycobutin Reduced cycloSPORINE exposure and reduced efficacy of cycloSPORINE Details Cyclosporine Ophthalmic Rifampin Rifadin Increased or reduced cycloSPORINE exposure and potentially an increased risk of organ rejection Details Cyclosporine Ophthalmic Rifapentine Priftin Reduced cycloSPORINE exposure and reduced cycloSPORINE efficacy Details Cyclosporine Ophthalmic Rimegepant Nurtec Increased exposure of rimegepant Details Cyclosporine Ophthalmic Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Cyclosporine Ophthalmic Ritonavir Norvir Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Rofecoxib An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Roflumilast Daliresp Increased roflumilast exposure and an increased risk of roflumilast-related adverse events Details Cyclosporine Ophthalmic Rolapitant Varubi Increased cycloSPORINE exposure Details